Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets
Authors not listed
Istituti Clinici Scientifici Maugeri SpA · 2026
Abstract
The goal of this observational study is to improve the understanding of the biological mechanisms underlying long COVID and to identify molecular biomarkers that may support its diagnosis, prognosis, and future precision medicine approaches in adults with long COVID, adults who have fully recovered from COVID-19, and healthy control participants.
The main questions it aims to answer are:
* What molecular, immunological, epigenetic, and microbiome profiles distinguish individuals with long COVID from recovered COVID-19 participants and healthy controls?
* How are viral persistence, immune dysregulation, and alterations in the gut-immune axis associated with the development and clinical manifestations of long COVID?
* Which molecular biomarkers may improve disease diagnosis, patient stratification, and the identification of potential therapeutic targets?
Participants will:
* Undergo clinical evaluation and provide information about their medical history and symptoms.
* Provide biological samples, including blood and, when clinically indicated, intestinal biopsy tissue collected during routine colonoscopy procedures.
* Undergo comprehensive molecular analyses, including immunological, epigenetic, transcriptomic, proteomic, and microbiome profiling.
* Have their clinical and molecular data integrated using advanced computational approaches to identify biological signatures associated with long COVID.
The results of this study may improve the understanding of the biological mechanisms underlying long COVID and support the development of novel biomarkers and future precision medicine approaches for diagnosis, prognosis, patient stratification, and therapeutic target identification.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-23 MST
Cite this
APA
Anonymous. (2026). Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets. <em>Istituti Clinici Scientifici Maugeri SpA</em>. https://clinicaltrials.gov/study/NCT07757620
Vancouver
Anonymous. Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets. Istituti Clinici Scientifici Maugeri SpA. 2026.
BibTeX
@misc{anon2026Epigen,
title = {Epigenetic Changes in Long COVID Patients: Unraveling the Gut-Immune Axis and Therapeutic Targets},
author = {Anonymous},
journal = {Istituti Clinici Scientifici Maugeri SpA},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Folia Microbiologica 2022
Open access · OA
Disease-associated dysbiosis and potential therapeutic role of Akkermansia muciniphila, a mucus degrading bacteria of gut microbiome
Aging 2025
Open access · CC-BY
Development of a novel transcriptomic measure of aging: Transcriptomic Mortality-risk Age (TraMA)
Cells 2023
Open access · CC-BY
Epigenetic Mechanisms of Aging and Aging-Associated Diseases
Clinica Universidad de Navarra, Universidad de Navarra 2021
Open access · US-GOV
Study of the Efficacy of a New Nutritional Supplement, Compared with Placebo, in Promoting Active and Healthy Aging from the Age of 65
Psychosomatic Medicine 2023
Preprint · OA
Short Sleep and Insomnia Are Associated With Accelerated Epigenetic Age
Cells 2024
Open access · CC-BY